On Apr. 17, 2020, Incyte announced the initiation of RUXCOVID, a global, randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC) in patients aged =12 years with COVID-19 associated cytokine storm.

The collaborative study is sponsored by Incyte in the United States and Novartis outside of the U.S.